Cost-utility analyses of atypical neuroleptics: A review;Kosten-nutzen-analysen "atypischer" neuroleptika

Psychopharmakotherapie

Volumn 8, Issue 4, 2001, Pages 138-143

  Schutz C ^a   Laux, G ^a   Gunther W ^a  

^a Kinderurologie und Roboterassistierte Minimalinvasive Urologie   (Germany)

Author keywords

Atypical neuroleptics; Cost of life quality; Cost utility analysis; Direct cost of illness; Indirect cost of illness

Indexed keywords

AMISULPRIDE; BENPERIDOL; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BUDGET; COST CONTROL; COST UTILITY ANALYSIS; DRUG EFFICACY; GERMANY; HOSPITAL PATIENT; HUMAN; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 18344416876     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Cost-effectiveness of clozapine. A UK clinic-based study
2. Reduction of health care resources utilization and cost following the use of risperidone for patients previously treated within standard antipsychotic therapy
3. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol
4. The EPSILON study of schizophrenia in five European countries. Design and methodology for standardising outcome measures and comparing patterns of care and service costs
5. Etude médico-économique du leponex (clozapine) au centre hospitalier Charles Perrens de Bordeaux
6. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs
7. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol
8. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom
9. Risperidone versus haloperidok: II. Cost-effectiveness
10. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals
11. Risperidone. A pharmacoeconomic review of its use in schizophrenia
12. Olanzapine. A pharmacoeconomic review of its use in schizophrenia
13. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
14. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial
15. Pharmacoeconomics of antipsychotic drug therapy
16. Health care reform for Americans with severe mental illnesses: Report of the National Advisory Mental Health Council
17. A two-year clinical and economic follow-up of patients on clozapine
18. Risperidone versus typical antipsychotic medication for schizophrenia
19. Direkte und indirekte kosten der schizophrenie
20. Comparaison économique de l'olanzapine versus haloperidol dans le traitement de la schizophrénie en France
21. Antipsychotic drug use patterns and the cost of treating schizophrenia
22. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
23. Einfluß kombinierter pharmako- und psychotherapie in einer schizophrenie-ambulanz auf rehospitalisierungszeiten und behandlungskosten
24. Gesamtkrankenkosten der schizophrenie und monetäre bewertung einer rezidivprophylaxe am beispiel eines standard-depot-neuroleptikums (flupentixoldecanoat)
25. A cost-effectiveness clinical decision analysis model for schizophrenia
26. Effect of risperidone on one-year hospitalization rates for patients with chronic schizophrenia
27. Pharmacoeconomics of clozapine, risperidone and olanzapine: A review of the literature
28. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients
29. Die kosten der schizophrenie
30. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
31. Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia
32. Untersuchungen zu den direkten und indirekten kosten der schizophrenie. Eine empirische analyse
33. Effects of a limit on medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia
34. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
35. An economic evaluation of schizophrenia-1991
36. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia